Top Biotech Companies With Best Stability & Growth (3,415)
.png)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products.
GRAIL's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show year-over-year increases in revenue and test volumes through 2025 and early 2026. Expanding U.S. adoption and rising Galleri volumes are cited as key contributors.
Strategic Partnerships: Announcements include Epic EHR integration to streamline ordering and results across many health systems, supporting broader access. International and channel collaborations, including Samsung-linked expansion plans, are positioned to extend reach.
Investor Backing & Capital Strength: Post–Illumina spin‑off funding and subsequent equity raises point to a multiyear cash runway. Additional financing provides flexibility to pursue regulatory, reimbursement, and commercialization goals.
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform...
SOPHiA GENETICS's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is accelerating with consistent year-over-year gains and guidance pointing to continued expansion through 2026. Record platform activity and rising deal momentum reinforce top-line trajectory.
Customer Loyalty & Retention: Net dollar retention has improved alongside growth in core genomics customers, indicating expanding usage among existing accounts. Record analyses and repeat adoption across cohorts suggest durable engagement.
Market Expansion: Expansion in the U.S. and APAC and the addition of large integrated health systems support a broader geographic and enterprise footprint. Increasing uptake of newer applications strengthens presence across regions.
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This...
Click Therapeutics's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Recent Series C (March 2025) from Dassault Systèmes/Medidata and a $50M Series D (April 2026) funded by Boehringer Ingelheim demonstrate continued access to capital aligned with commercialization plans. Long-standing pharma ties with Otsuka and Boehringer, including sizable milestone frameworks, further reinforce capital strength.
Product Line Growth: Two FDA-authorized products (Rejoyn for MDD; CT-132 for migraine) and a Phase 3–positive schizophrenia PDT (CT-155) expand the portfolio from R&D into early commercialization. Acquisitions and new offerings (Better Therapeutics’ AspyreRx IP and the Click SE initiative) broaden therapeutic scope.
Strategic Partnerships: Enduring alliances with Otsuka and Boehringer, plus a strategic integration investment from Dassault Systèmes/Medidata, indicate strong external validation and go-to-market support. Category-shaping moves like Click SE (aligned with FDA PDURS) aim to deepen co-labeling and pharma collaboration opportunities.
Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the...
Benchling's Top Stability & Growth Strengths
Strong Market Position & Advantage: Public materials consistently cite more than 1,300 organizations on the platform, including global pharmas like Merck, Moderna, and Sanofi. This breadth and logo depth indicate entrenched presence across modern biotech R&D.
Innovation-Driven Growth: The company continues launching new capabilities (e.g., Benchling Models, Biologics updates, Validated Cloud) and reports broad uptake of Benchling AI after GA, suggesting expanding use cases across its base. Ecosystem moves like one‑click ordering integrations point to product‑led expansion.
Strong Revenue Growth: Independent estimates describe ARR above $200M in 2024 and increasing year over year. This supports a view of continued top‑line expansion despite a tougher market context.
We bring together one of the world’s largest libraries of multimodal clinical and molecular data with a robust suite of AI tools to help physicians personalize care in real time, connect patients with therapies and clinical trials, and enable partners to accelerate discovery and development of new treatments. With ~8 million de-identified research records and 350+ petabytes of data, Tempus partners...
Tempus AI's Top Stability & Growth Strengths
Strong Revenue Growth: Reported revenue increased sharply in 2025 and continued to rise in Q1 2026, with management raising full‑year 2026 revenue guidance and signaling improved operating leverage.
Diversified Revenue Streams: Both Diagnostics and the higher‑margin Data & Applications businesses showed growth in recent updates, indicating multiple engines driving the top line.
Strategic Partnerships: The company expanded multi‑year collaborations with major pharmaceutical firms and highlighted a sizable pipeline and contract values that support future demand.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
Flatiron Health's Top Stability & Growth Strengths
Product Line Growth: The May 2026 launch of Flatiron Telescope, an AI analytics platform built on multi‑country longitudinal oncology data, signals active expansion of the product portfolio. Additional 2026 Panoramic prostate cancer datasets spanning the US, UK, and Germany reinforce new offerings.
Strategic Partnerships: Abbott’s March 2026 integration of its precision oncology testing directly into OncoEMR indicates deeper, EMR‑embedded collaborations at the point of care. Such integrations suggest widening partner‑driven reach in community oncology workflows.
Market Expansion: Company materials describe a larger technical and geographic footprint in 2026, with datasets and platforms spanning the US, UK, Germany, and Japan. New cross‑country datasets (e.g., Panoramic prostate cancer) indicate scaling of international real‑world data assets.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: A $372M Series D in June 2024 led by a16z with Sanofi participation provides substantial capital to expand the pipeline and AI capabilities. Reports characterize this as a material valuation step-up and part of a sizable overall funding base.
Strategic Partnerships: A first-of-its-kind AI collaboration with Sanofi and OpenAI and an out‑licensing deal of gusacitinib to Sanofi (up to €545M) indicate strong external validation and access to enterprise-scale deployment. These alliances reinforce market credibility while opening channels for co-development and monetization.
Product Line Growth: Ongoing in‑licensing (e.g., a CNS‑penetrant TYK2 inhibitor and an anti‑CD226 program) and 2026 updates showing rapid Phase 1 initiation suggest a broadening and advancing portfolio. The rebrand and model shift aim to support a faster-moving, diversified pipeline across immunology and related areas.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for...
Pfizer's Top Stability & Growth Strengths
Product Line Growth: Evidence indicates non‑COVID brands and newly launched/acquired assets are expanding, with growth led by Eliquis, Vyndaqel/Vyndamax, oncology biosimilars, Nurtec, and Seagen‑originated therapies such as Padcev.
Future-Ready Strategy: Company materials highlight the Seagen acquisition as a multi‑year oncology growth engine alongside recent approvals and advancing vaccine programs, with numerous pivotal starts planned to add future contributors.
Cost & Operational Efficiency: Disclosures describe a multi‑year cost realignment targeting substantial net savings, alongside deleveraging priorities and expected integration synergies to support margin stability during the revenue mix shift.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Full‑year 2025 total revenue rose 23% to $255.9M with software up 11%, highlighting broader adoption and upsell including more hosted deployments. ACV reached $201M on a trailing four‑quarter basis and grew 12% in Q1 2026, with 2026 ACV guided to 10–15% growth.
Strategic Partnerships: Progress in collaborations and co‑founded or partnered programs lifted drug‑discovery revenue (Q1 2026 more than doubled, and 2026 guidance is $55–$65M). The company is pursuing partnerships for oncology assets SGR‑1505 and SGR‑3515 and highlighted potential milestone and liquidity events.
Future-Ready Strategy: Management is transitioning software from term licenses to hosted subscriptions and outlined 2026 priorities to scale the “physics+AI” platform and release the Bunsen agentic AI “co‑scientist.” Feedback suggests this shift should aid scalability and retention even as near‑term revenue recognition is choppy.
At Inato, we’re on a mission to accelerate the pace of medical innovation by bringing clinical research to each and every patient, regardless of who they are and where they live. Our platform, made to connect community-based research centers to trials across the globe, aims to create greater visibility, access, and engagement across a more diverse population of doctors and...
Inato's Top Stability & Growth Strengths
Market Expansion: Public materials indicate the network has expanded to 6,000+ research sites across 50+ countries and 25+ sponsors, up from 5,500+ sites cited in late 2025. This footprint growth signals broader geographic reach and increasing demand-side participation.
Strategic Partnerships: Announced partnerships such as the September 2025 RealTime eClinical data-integration open access to 50+ large site networks (2,000+ sites) and enrich marketplace data. Additional integrations (e.g., eClinPro in 2026) reinforce distribution and embed the platform more deeply in site workflows.
Innovation-Driven Growth: The company launched AI-enabled pre-screening, AI site selection, and EHR integration in 2025–2026 to improve patient identification and sponsor decision-making. These capabilities can increase conversion and make the platform more attractive to both sites and sponsors.
Scout Clinical’s mission is to make it easier for patients to participate in clinical trials. From travel arrangements and payment management to regulatory review and special services, we do it all.
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from rare hematologic and musculoskeletal disorders with high unmet medical need
Excelya is an independent partner that serves Biotech, Pharma, and Medical Device organizations with a comprehensive range of Full-service CRO, FSP, and Resourcing solutions guided by compassion, care, and excellence. Founded in 2014 and headquartered in Paris, France, and operating in 28 countries across Europe, USA and India, Excelya has a global team of 900+ experts who understand the critical...
Enviromedica is an innovative natural health and wellness company that applies science-based evolutionary theory to create foundational support products. They focus on ancestral health, microbiome support, and rewilding the gut.
Bavarian Nordic is a global biotechnology company focused on the development, manufacturing, and commercialization of innovative vaccines, with a mission to improve health and save lives.
ZAGENO is on a mission to accelerate scientific innovation by streamlining biotech purchasing processes with its award-winning, first-of-its-kind e-commerce platform. With over 25 million product SKUs available from more than 5,000 unique product brands, ZAGENO makes online shopping for any research material convenient, efficient and reliable. The ZAGENO experience includes its Scientific Score, a best-in-class product rating system that offers...
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve...
Avantor's Top Stability & Growth Strengths
Strong Market Position & Advantage: Disclosures describe one of the two largest global lab distributors via VWR with broad reach into research and production labs worldwide and deep embedment in biopharma workflows. This positions the company as a top-tier player in lab distribution and life-science consumables even if not the overall market leader.
Healthy Cash Flow: Recent updates highlight strong free-cash-flow conversion and deleveraging exiting 2024. Management emphasized ongoing cash generation alongside margin improvement.
Cost & Operational Efficiency: Management is executing multi-year cost programs with margin improvement evident in late 2024. Efficiency actions and portfolio focus are intended to support profitability despite uneven demand.
Kingdom creates and sells natural functional ingredients that actually work. Our Superculture® ingredients are an entirely new class of clinically-validated postbiotics that target the root causes of unmet health needs. Superculture® Pet Oral and Superculture® Pet Immune are our first two breakthrough ingredients for pet health, driving industry-leading efficacy and unlocking new marketing claims for brands. We've partnered with a...
